Opiant Pharmaceuticals (OPNT) Releases Earnings Results, Misses Expectations By $0.21 EPS

Opiant Pharmaceuticals (NASDAQ:OPNT) posted its quarterly earnings data on Wednesday. The technology company reported ($0.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.21), Fidelity Earnings reports. Opiant Pharmaceuticals had a negative net margin of 449.52% and a negative return on equity of 471.43%. The firm had revenue of $4.37 million during the quarter, compared to the consensus estimate of $4.70 million.

NASDAQ OPNT traded down $0.32 on Thursday, hitting $17.03. 13,254 shares of the company were exchanged, compared to its average volume of 41,092. The firm has a market cap of $49.01 million, a PE ratio of 5.79 and a beta of 0.34. Opiant Pharmaceuticals has a 12 month low of $12.75 and a 12 month high of $36.27.

In other Opiant Pharmaceuticals news, CEO Roger Crystal sold 10,847 shares of the company’s stock in a transaction on Tuesday, October 9th. The shares were sold at an average price of $17.21, for a total transaction of $186,676.87. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Phil Skolnick sold 4,778 shares of the company’s stock in a transaction on Thursday, October 4th. The stock was sold at an average price of $18.32, for a total transaction of $87,532.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,896 shares of company stock worth $641,136. 63.82% of the stock is owned by insiders.

A hedge fund recently bought a new stake in Opiant Pharmaceuticals stock. Brasada Capital Management LP acquired a new position in shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,000 shares of the technology company’s stock, valued at approximately $268,000. Brasada Capital Management LP owned about 0.50% of Opiant Pharmaceuticals at the end of the most recent quarter. 4.51% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently issued reports on OPNT. ValuEngine lowered shares of Opiant Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 28th. Cantor Fitzgerald set a $42.00 target price on shares of Opiant Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, September 28th.

TRADEMARK VIOLATION WARNING: “Opiant Pharmaceuticals (OPNT) Releases Earnings Results, Misses Expectations By $0.21 EPS” was reported by WKRB News and is the property of of WKRB News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.wkrb13.com/2018/11/09/opiant-pharmaceuticals-opnt-releases-earnings-results-misses-expectations-by-0-21-eps.html.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Recommended Story: Consumer behavior in bull markets

Earnings History for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply